The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes and efficacy of HER2-targeted therapy in breast cancer with uncommon in situ hybridization (ISH) patterns or discordant immunohistochemistry (IHC).
 
Qianchen Zhang
No Relationships to Disclose
 
Jincong Q. Freeman
No Relationships to Disclose
 
Fangyuan Zhao
No Relationships to Disclose
 
Nan Chen
Employment - GlaxoSmithKline (I)
Consulting or Advisory Role - AstraZeneca; GE Healthcare; Gilead Sciences; Guardant Health; Seagen; Stemline Therapeutics
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Merck; Moderna Therapeutics; Novartis; Sanofi; Seagen; Stemline Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Dezheng Huo
No Relationships to Disclose
 
Frederick Matthew Howard
No Relationships to Disclose